Ovarian Cancer / 06.06.2014
Ovarian Cancer: Using a Genetic Signature To Predict Response to Bevacizumab
MedicalResearch.com Interview with:
Sean C. Dowdy, MD, FACS
Professor and Chair, Division of Gynecologic Surgery
Vice-Chair for Research, Department of Obstetrics and Gynecology
Co-Leader, Women’s Cancer Program
Mayo Clinic College of Medicine
MedicalResearch.com: What are the main findings of the study?
Dr. Dowdy: This study was a collaboration between four groups in 3 countries to determine if a genetic “signature” could predict which patients with ovarian cancer benefit from Bevacizumab (a very expensive drug with marginal benefit in patients with ovarian cancer). We hypothesized that while benefit may be marginal in a large group, patients with specific genetic changes could derive significant benefit from it. Using gene expression arrays (analyzing over 18,000 genes) we separated patients into four subgroups as described by The Cancer Genome Atlas (TCGA). We show that patients in the proliferative and mesenchymal groups had a 8-10 month improvement in outcome compared to a 3 month improvement for the other two groups (immunoreactive and differentiated).
(more…)